WO2014047278A1 - Procédé de détermination de la réponse immunitaire cellulaire aux vaccins thérapeutiques - Google Patents

Procédé de détermination de la réponse immunitaire cellulaire aux vaccins thérapeutiques Download PDF

Info

Publication number
WO2014047278A1
WO2014047278A1 PCT/US2013/060606 US2013060606W WO2014047278A1 WO 2014047278 A1 WO2014047278 A1 WO 2014047278A1 US 2013060606 W US2013060606 W US 2013060606W WO 2014047278 A1 WO2014047278 A1 WO 2014047278A1
Authority
WO
WIPO (PCT)
Prior art keywords
ima
biological sample
immune
disease
cells
Prior art date
Application number
PCT/US2013/060606
Other languages
English (en)
Inventor
Bruce J. MCCREADY
Brad L. STEWART
Original Assignee
Viracor-Ibt Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viracor-Ibt Laboratories filed Critical Viracor-Ibt Laboratories
Publication of WO2014047278A1 publication Critical patent/WO2014047278A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the invention generally relates to methods for assessing the state of a subject's immune system after administration of an immune stimulant or inhibitor of interest in order to evaluate, monitor, or treat a disease or condition, e.g. a cancer vaccine.
  • the invention provides methods for detecting a product or patterns of products produced by the immune cells of the subject in response to administration of the immune stimulant or inhibitor; the products or pattern of products that is detected serves as an indicator of the subject's functional immune response to treatment.
  • a vaccine may be generally defined as a biological preparation that improves immunity to a particular disease.
  • Vaccines typically contain at least one agent that resembles or contains portions of a disease-causing entity, or an entity that is characteristic of a disease.
  • the agent stimulates the subject's immune system to recognize the agent (and hence the disease-related entity which it resembles) as foreign, destroy it, and "remember” it. Thereafter, the immune system can more easily recognize and destroy similar disease-related entities when they are encountered.
  • Vaccines can be prophylactic (e.g. intended to prevent or ameliorate the effects of a future disease), or therapeutic (e.g. intended to treat or ameliorate the effects of incipient or established disease).
  • Therapeutic vaccines are currently of great interest, with some promising vaccine candidates having already been developed and approved for use by the United States Food and Drug Administration (FDA).
  • FDA United States Food and Drug Administration
  • current methods for monitoring the efficacy of therapeutic vaccines, and hence to guide medical practitioners' use of the same, are rudimentary at best.
  • IVD in vitro diagnostic
  • IVD assays are proteomic in nature and are based on the measurement of molecular concentrations of proteins and/or peptides.
  • Computational analysis has been used to identify protein/peptide biomarkers and expression patterns of multiple biomarkers with clinical utility. Incorporation of such biomarkers into data reduction algorithms that facilitate actionable clinical decision making has greatly improved the utility of protein/peptide biomarkers in multiplex IVD assays.
  • assays that are currently widely used for analyzing cellular immune responses remain rudimentary. They are often not based on protein/peptide multiplex assays, but instead, most simply measure the extent of redness and swelling at the injection site following administration of the vaccine or components of the vaccine under the skin, count the number of cells present, or use traditional methods to characterize cell types present as a percentage of the total white blood cell count, as with the classical complete blood count.
  • the invention provides methods and assay kits for determinations of the immune status of a subject before, and after, at least one administration of an immune modulating agent (IMA) to the subject, for example, to evaluate a patient's immune status prior to administration of an IMA to determine if they are a good candidate for the treatment, to evaluate how a patient is responding to treatment with the IMA, and for other reasons as part of, for example, a treatment for a disease or condition of interest.
  • the methods and assays of the invention may provide a way to assess whether or not the administration of the IMA has had a desired effect on the subject, e.g. stimulating or inhibiting the immune system of the subject.
  • the methods and assays may have wide applicability and may be used in clinical settings as a tool for evaluating and/or monitoring the effectiveness of treatments which modify the immune system.
  • an IMA is administered to a subject, typically a subject that has or is at risk of developing a disease or condition of interest. Thereafter, a biological sample is obtained from the subject. Immune cells in the sample are then exposed to (stimulated by) the IMA in vitro and the functional response of the immune cells to the IMA is determined. In some embodiments, a biological sample will also have been obtained from the subject prior to the first administration of an IMA and tested using the invention in order to establish a
  • patient-specific baseline i.e. prior to treatment
  • functional response pattern that can be compared with the pattern observed after administration of an IMA.
  • a patient's immune status prior to administration of an IMA is determined.
  • a biological sample is obtained from the patient and is exposed to (stimulated by) the IMA in vitro and the functional response of the immune cells to the IMA is determined. Based on the response, a clinician may be able to identify if the patient is a good candidate for the treatment.
  • the immune cells are separated from the biological sample prior to IMA exposure.
  • the biological sample as a whole is exposed to the IMA and the immune cells are separated from the sample afterwards, prior to assessment of the products they produce.
  • the immune cells are not separated from the sample, e.g. an on-board cell capture/labeling and analyte detection system is employed.
  • the functional immune response of the immune cells may be determined by multiplex detection of a plurality of products or analytes produced by the immune cells in response to stimulation by the IMA.
  • the group of products that is detected may be referred to herein as a "pattern”, “pattern of expression”, “functional response pattern”, or other similar terms.
  • the pattern of analytes that is detected is compared to a predetermined, characteristic (i.e. expected) response pattern that was previously established in control subjects.
  • a predetermined, characteristic i.e. expected
  • immune cells in the biological sample will produce a characteristic, predetermined detectable pattern of products in response to in vitro exposure to the IMA(s).
  • a trained medical practitioner may conclude that the treatment of the subject with IMA was successful, e.g. the immune cells of the subject have been successfully primed to produce a desired set of products by administration of the IMA.
  • administration of the IMA to the subject was not effective, then the immune cells in the biological sample will not respond to stimulation by the IMA by producing the desirable pattern of products.
  • This latter outcome may result in a conclusion, by trained medical personnel, that IMA administration should be repeated, or repeated in a different manner (e.g. with a higher dose, with different IMA(s), etc.), that a different type of treatment should be tried to treat the disease, or that the treatment protocol should be altered in some other manner.
  • the functional response pattern of a subject may be different after treatment with the IMA than it was prior to treatment with the IMA, and this difference could be evaluated with respect to whether the change in the functional response pattern is expected or not expected.
  • Figure 1 Schematic representation of the administration of IMA(s) to a subject and the subsequent in vitro detection of, as an exemplary embodiment, a pattern of products produced by immune cells from the subject.
  • the invention provides methods and assays for interrogating the immune status of an individual before and/or after administration of at least one immune modulating agent (IMA) (a therapeutic immune stimulant or inhibitor).
  • IMA immune modulating agent
  • the methods and assays detect, in vitro, whether or not prior in vivo administration of the IMA to the subject caused cells in the immune system of the subject to respond in a desired manner. If the IMA is an immune stimulant, the intended result is that the immune cells become competent to mount a successful immune response to the IMA. If the IMA is an immune inhibitor or suppressant, then the desired response may be a decrease in responsiveness of the immune cells or production of a pattern of analytes associated with suppressive response from the immune cells.
  • At least one product (or a pattern of products) associated with at least one immunological response to the IMA is detected and/or is detected in expected amounts when immune cells obtained from the subject are exposed to the IMA, or one or more components of the IMA in vitro, then one may conclude that the previous administration of the IMA to the subject did result in activation (or suppression) of the immune system with respect to the IMA. In this embodiment, if the product is not detected or the expected pattern of analytes is not observed, the previous administration was not successful.
  • a pattern of biomarker molecule production (a plurality of products is detected) similar to a predetermined desired pattern is preferably detected when immune cells obtained from the subject are exposed to the IMA, or one or more components of the IMA, in vitro.
  • detecting the pattern of biomarker molecule production one may conclude that the previous administration of the IMA to the subject did result in activation (or suppression) of the immune system with respect to the IMA.
  • the characteristic biomarker pattern is not detected, then it may be concluded that the IMA administration was not successful, i.e. the immune system of the subject did not mount a successful response to the IMA, or was not inhibited.
  • the IMA is, for example, a mimic of a disease causing entity (e.g. an infectious agent) or of an entity associated with a disease (e.g. a cancer cell), medical or clinical personnel may use this information to conclude whether or not it is likely that the immune system of the subject will mount a successful response to, and hence eliminate, the disease causing entity or the entity associated with a disease, when encountered in the future.
  • a disease causing entity e.g. an infectious agent
  • an entity associated with a disease e.g. a cancer cell
  • the IMA is an immune inhibitor
  • medical or clinical personnel may use this information to conclude whether or not the immune system has been sufficiently repressed.
  • a patient's immune status prior to administration of an IMA is determined.
  • a biological sample is obtained from the patient and is exposed to (stimulated by) the IMA in vitro and the functional response of the immune cells to the IMA is determined. Based on the response, a clinician may be able to identify if the patient is a good candidate for the treatment.
  • IMA immune modulating agent
  • IMAs may stimulate the immune system, or may inhibit the immune system.
  • the IMA or an IMA preparation, which may include multiple agents
  • antigens include but are not limited to those which occur in or on (e.g. on the surface of) or are otherwise associated with cells which it is desirable to eliminate from the body, e.g. infectious agents (bacteria, disease causing protozoans, viruses, fungi, etc.), cancer cells, auto-reactive cells, etc.
  • immune stimulating agents may be included in an IMA composition, examples of which include but are not limited to: nucleic acid sequences (e.g. CpG), polysaccharides, glycoproteins, lipoproteins, ligands that bind specific cellular receptors, cell surface ligands which bind to receptors on other cells but which do not function as receptors themselves, cellular receptor molecules (e.g. co-stimulatory receptors such as B7 and B7.1 ; inhibitory receptors such as CTLA-4, PD-1), mimics of natural cellular receptors, antibodies against cellular receptors, histocompatibility molecules (e.g. MHC class I and class II molecules), disease modified biomolecules (e.g. normal proteins with a mutated amino acid sequence, normal proteins with altered post-translational modifications such as phosphate or carbohydrate groups added, deleted, or attached at different positions than the normal biomolecule), etc.
  • nucleic acid sequences e.g. CpG
  • polysaccharides e.g. Cp
  • a biological sample from the patient or subject that received or will receive the IMA is used.
  • the sample is exposed to either the IMA or one or more components of the IMA.
  • the IMA comprises cancer cell antigens in the form of antigenic proteins or peptides from or associated with cancer cells, and
  • Tumor antigens are generally divided into two broad categories: shared tumor antigens; and unique tumor antigens. Shared antigens are expressed by many tumors, whereas unique tumor antigens result from mutations induced through physical or chemical carcinogens, and are therefore expressed only by individual tumors.
  • Therapeutic cancer vaccines against both categories of tumor antigens are currently being developed for the treatment of breast, lung, colon, skin, kidney, prostate, and other cancers. In yet another approach, a cancer vaccine may contain whole tumor cells.
  • the assays of this invention which could include either shared or unique tumor antigens as the IMA (or components thereof) which is added to the biological sample from the patient that is receiving or will receive treatment with the IMA can help assess whether the cancer patient will be a good candidate for treatment with the IMA, help assess the dosing of the IMA provided to the patient during treatment, and help in assessing that the treatment is progressing in a desired or non-desired manner.
  • the amount of an IMA that is administered to a subject may vary from subject to subject, from IMA to IMA, or for other reasons, and that skilled medical professionals (e.g. physicians or other medical or clinical personnel) will be able to determine the amounts or range of amounts.
  • the suggested amount may be determined using methodology known to those of skill in the art, e.g. using data obtained in clinical trials.
  • Those of skill in the art will also recognize the caveats associated with administration, e.g. in the case of administering antigens, the amount or conditions should be sufficient to avoid the development of tolerance to the antigen in the subject.
  • BioVex Inc product OncoVEX GM-CSF is a version of herpes simplex virus which is genetically engineered to replicate selectively in tumor tissue and to express the immune stimulatory protein
  • GM-CSF granulocyte-macrophage colony-stimulating factor
  • the IMA may be an immune inhibiting agent.
  • the IMA is administered e.g. to persons with an autoimmune disease.
  • exemplary inhibiting agents that may be included in an IMA include but are not limited to anti-CTLA-4, antibodies that block binding or transit of cells into tissues (e.g. anti-integrin antibodies) or cell differentiation (e.g. IL-2, TLRs) factors, agents that block that activity of
  • pro-inflammatory proteins e.g. anti-T F-a, anti-IL-lR
  • inhibitors of intracellular cell signaling pathways associated with immune response e.g. mTOR, JAK/STAT
  • inhibitors of metabolism e.g. MTX
  • the invention encompasses assays which indicate the immune status of a subject prior to and/or in response to (i.e. after) administration of an IMA.
  • the product(s) associated with an immunological response can be identified from medical resource materials, or can be identified in the practice of this invention by testing biological samples from control subjects (apparently healthy people as well as people with the disease or suspected of having the disease but not treated with the IMA) as well as biological samples obtained following administration of the IMA to subjects with the disease or suspected of having a disease, and based on testing of biological samples of these subjects identifying at least one product which is common for all or a majority or a significant fraction of the subjects with the disease or suspected of having the disease (i.e., the product is in a sample from every subject or a majority of the subjects).
  • a pattern of products could be identified by detecting a plurality of different products, one or more of which is in a sample from, for example, all or a majority or a significant fraction of the subjects).
  • An embodiment of the invention contemplates using the assay to identify people capable of responding to an IMA, and which are therefore good candidates for receiving the IMA as a treatment regimen.
  • biological samples from a plurality of candidates would be exposed to the IMA or a component thereof, and, based on the detection or non-detection of expected product(s) associated with the immunological response, a subject can be identified as a good candidate to receive treatment with the IMA.
  • multiplex we mean an assay that simultaneously measures properties of multiple analytes or chemical compounds (e.g.
  • biomolecules of interest e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more
  • analytes generally include biological products (chemical compounds, etc.) that are produced by immune cells.
  • control expression patterns may be determined based on results obtained in control subjects.
  • Exemplary control subjects may include, but are not limited to, e.g. subjects who are free of the disease or condition of interest and who have never received the IMA;
  • subjects who are free of the disease/condition of interest and who have previously received the IMA subjects confirmed as having the disease/condition of interest but who have never been treated by the IMA; and/or subjects confirmed as having the disease of interest who have been treated by the IMA (e.g. subjects who have been successfully and/or
  • the exemplary multiplex analyte patterns of the invention are generally "characteristic of or "associated with" functional response patterns of individuals who respond positively to exposure to the IMA.
  • the exemplary multiplex analyte patterns which are desired are those associated with functional response patterns of individuals who respond positively to exposure to the IMA (e.g., activated for a therapeutic cancer vaccine, or suppressed for an autimmune disease like MS, RA, and IBD).
  • a tumor e.g., a therapeutic cancer vaccine
  • an autoimmune response e.g., in MS, RA, or IBD
  • the exemplary multiplex analyte patterns which are desired are those associated with functional response patterns of individuals who respond positively to exposure to the IMA (e.g., activated for a therapeutic cancer vaccine, or suppressed for an autimmune disease like MS, RA, and IBD).
  • Those of skill in the art are familiar with techniques for identifying previously unknown
  • this is usually accomplished by multiplexing, using known techniques, a number of biological samples from control individuals as described above.
  • This may include both the accumulation of data from positive controls (subjects whose immune systems respond "normally” to IMA exposure, e.g. by attacking cancer cells, or by not attacking the subject's tissues in the case of autoimmune diseases, etc., who may be referred to herein as
  • control subjects may be matched based on age, gender, genotype, ethnicity, medical and health history, etc.
  • information obtained from a variety of subjects with various traits without accounting for such factors. In the case where age, gender, etc. are taken into account, the objective is generally to use information from such a group when analyzing data obtained in an experimental subject that also fits the group's profile.
  • Biomarkers that appear, for example, in a majority or a significant fraction, e.g., greater than at least about 50% of the positive control samples (or possibly in higher percentages, e.g. about 60, 65, 70, 75, 80, 85, 90, 95, or even 100% of positive control samples) but which do not appear in negative control samples, may be selected as biomarkers that can be used in the multiplex assays of the invention.
  • the difference between positive (responder) and negative (non-responder) controls may not be absolute in that negative controls may exhibit one or more of the biomarkers in the pattern, but in lesser amounts, e.g. in less than at least about 50% of the negative control samples (or possibly in lower percentages, e.g.
  • the biomarkers may occur with the same frequency (e.g. may be in 40% of both positive and negative controls samples) but the amount of biomarker is significantly greater in the positive control, e.g. the amount of a biomarker is about 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, lOx or even more (e.g. 50, 100, 500 or even lOOOx) abundant in the positive control than in the negative control.
  • a responder may have much less of a biomarker than a non-responder.
  • the total number of biomarkers in a multiplex of the invention may vary widely, but will generally be in the range of at least about 2, 3, 4, 5, 6, 7, 8, 9, 10 or more, e.g., 15, 20, 25, 30, 35, 40, 45, or 50 or more.
  • a biological sample is obtained from a subject to whom the IMA has been
  • the IMA or components thereof is or are used to stimulate the immune cells in the sample.
  • biological samples which are frequently but not always biological fluids such as blood (e.g. peripheral blood), serum, synovial fluid, saliva, urine, spinal fluid, tissues, fluids originated from disease sites etc.
  • various tissues may be sampled or be included in the sample, e.g. biopsy tissue samples.
  • co-stimulants such as phytohaemaglutinin (PHA), lipopolysaccharide (LPS), antigens, superantigens such as Staphylococcal enterotoxin A (SEA) and Staphylococcal enterotoxin B (SEB), anti-CD3, anti-CD28, etc. are also added to the reaction.
  • PHA phytohaemaglutinin
  • LPS lipopolysaccharide
  • SEB Staphylococcal enterotoxin B
  • anti-CD3, anti-CD28, etc. are also added to the reaction.
  • in vitro stimulants may be added directly to test samples and then incubated at the desired temperature such as 37°C for a suitable period of time (e.g. generally from about 0 to about 48 hours).
  • the stimulation condition and time may be optimized so the appropriate signal to noise ratio is obtained.
  • the stimulants may be prepared in solution, dried-down or lyophilized forms, and be supplied in the same collection tubes or in separate tubes.
  • assay controls may be included and run side by side with the test samples.
  • negative controls are generally included, e.g. the assay without IMA stimulation or with non-specific antigens.
  • Positive controls might be the assay plus a mitogen such as PHA, LPS, superantigens such as SEA and SEB, anti-CD3, anti-CD28, etc.
  • the functional response of the immune cells in the sample to the IMA is monitored, for example, by detecting or measuring the production of a plurality or panel of substances known to be associated with immune activation, i.e. substances known to be associated with functional immune responses.
  • the detected molecules may be produced specifically and exclusively in response to a particular IMA (or a specific antigen present in an IMA), or they may be produced in response to several different antigens in the IMA.
  • detected biomarker molecules may be general indicators of cell activation, examples of which include but are not limited to intracellular ATP, PCNA, and calcium ions as well as specific markers of immune cell responses such as interferon-gamma (IFN- ⁇ ), interleukin-2 (IL-2), various micro-RNA (miRNA) or messenger RNA (mRNA) molecules.
  • the immune cells present in a biological sample which may be interrogated using the multiplex assay of the invention include but are not limited to various populations or subpopulations such as: B cells, T cells, various subpopulations of B and/or T cells, monocytes, macrophages, dendritic cells, etc. Further, profiles or panels of markers from two different cell types from a patient may be compared, e.g.
  • T helper cells vs T regulatory cells, or T regulatory cells vs B regulatory cells, etc.
  • one or more subpopulations of immune cells such as CD4+ or CD8+ may be used in the assay, or specific profiles associated subpopulations of immune cells may be measured.
  • biomarker molecules which may be detected include but are not limited to: IFN- ⁇ , cytokine profiles or panels of markers, intracellular ATP concentration or other cell functions as the result of immune cell activation, etc.; the expression products of one or a plurality of genes e.g. one or a plurality of mRNA molecules, which may generate a unique, detectable mRNA profile; one or a plurality of miRNAs may generate a unique, detectable miRNA profile; one or a plurality of protein or peptides, which may generate a unique, detectable protein/peptide profile; one or more substances that are produced by activated immune cells in response to exposure to an activating antigen such as an IMA, e.g.
  • an activating antigen such as an IMA
  • ATP ATP
  • IFN- ⁇ glucose
  • NADH oxidized glutathione
  • Those of skill in the art are familiar with techniques for detecting such molecules, e.g. using ELISA, nucleic acid amplification (e.g. PCR), sequencing of peptides/proteins and/or nucleic acids, HPLC analyses, gel electrophoresis and staining, mass spectrometry, etc.
  • the IMA is an immune stimulating agent and a positive functional immune response is detected
  • the amount of biomarker that is detected will generally increase, although this need not always be the case, since stimulation of some responses may attenuate expression of others.
  • the IMA is an immune inhibitor
  • the amount of biomarker that is detected will generally decrease, although this too may not always be the case, since a decrease in the amount of one substance may cause a compensatory increase in one or more other substances.
  • interpretation of the results obtained using the assays and methods of the invention are facilitated by provision of a "scale” or “rating system” based on results obtained with control subjects.
  • the quantity or level (i.e. the measured or detected amount) of substances produced by stimulated cells may be compared, e.g. on a scale of 1 to 10, with the amount that is typically or on average detected in negative control subjects e.g. 2 or less, and the amount for positive control subjects, e.g. 8 or more.
  • Other intermediate response values may be assigned numeric values of e.g. 3-7, with 3 being the mildest response and 7 being the strongest. Such values may also be used as target values for treatment, e.g.
  • a reasonable target range to attain by using IMA administration might be preferably 8 or more, if no side effects are experienced from the IMA treatment.
  • numeric reference systems e.g. 1-100, using decimals e.g. 1.0 to 10.0, or percentages, etc., including "all or nothing" binary systems where a simple "yes” or “no” answer is provided to the question: Is a functional immune response detected?) and all such expression systems are intended to be encompassed by the present invention.
  • the use of such scales may facilitate automation of the assays of the invention.
  • the scale of results may also be expressed in the format of a ratio in which the numerator is the measured response (e.g. cytokine) and the denominator is a unit of measurement of the sample (e.g. volume, # of cells, per cell, etc.).
  • the numerator is the measured response (e.g. cytokine) and the denominator is a unit of measurement of the sample (e.g. volume, # of cells, per cell, etc.).
  • the final step in one embodiment of the method involves interpreting and then drawing a conclusion from the results of the assay. If a pre-determined characteristic pattern of biomarkers is detected, then it is likely that the subject's immune system is responding to the IMA in a favorable or desired manner. For example, if the desired response is immune stimulation, then the subject may mount a robust immune response to the IMA. This may bode well for the subject, as they are also then likely to mount a robust immune response to the entity represented or mimicked by the IMA. Conversely, for IMAs that are designed to inhibit one or more immune responses (e.g.
  • the pattern may indicate a cessation or lessening of one or more immune response indicators if administration is successful.
  • the pre-determined characteristic pattern of biomarkers is not detected when an increased response is desired, or if a characteristic pattern is still detected when a decreased response is desired, then administration of the IMA has not been successful, and other treatment strategies may need to be considered.
  • the detected results are compared results that are obtained in at least one of:
  • the multiplex assays are used for immediate monitoring in the aftermath of IMA administration, e.g. a biological sample is obtained and assessed at from about 1 or 2 to about 30 days (e.g. about 1 , 2, 5, 10, 15, 20, 25 or 30 days) after administration of the IMA.
  • the patient's response to IMA administration is monitored thereafter, e.g. at intervals of several days, weeks or months, or even indefinitely, e.g. at twice-yearly or yearly intervals, in order to monitor and assess the state of the immune system of the patient on an ongoing basis. If and when a decrease in immune response is detected (or an increase, in the case of administration of an immune inhibitor), then the IMA may be re-administered to boost (or inhibit) the immune response.
  • the immune system status of an individual with a number of different diseases or conditions may be determined using the methods of the invention, including but not limited to: cancer, various infectious diseases, various immune disorders, autoimmune diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), multiple sclerosis (MS), etc.
  • IBD inflammatory bowel disease
  • RA rheumatoid arthritis
  • MS multiple sclerosis
  • the immune status of an individual with any condition or constellation of symptoms that is/are generally recognized by health care professionals as being detrimental to, or potentially detrimental to, the health and well-being and/or longevity and/or quality of life of an individual, and which may be treated by administration of an IMA may be subject to analysis using the methods and assays described herein.
  • the overall workflow including IMA administration, sample collection, stimulation and cell function measurement may be adapted to an automated platform(s).
  • a gene or protein chip which binds and measures nucleic acids or proteins, respectively, may be used to detect a partem of products, etc.
  • IMA stimulation might be necessary or desirable for obtaining or to maximize specific and reproducible functional immune responses.
  • the invention provides a method of assessing the efficacy of a vaccine such as a cancer vaccine.
  • a vaccine such as a cancer vaccine.
  • a cancer vaccine typically are comprised of antigens derived from cancer cells, or cancer cells that have been inactivated, or portions of cancer cells, etc. While the invention has been described in terms of its preferred embodiments, those skilled in the art will recognize that the invention can be practiced with modification within the spirit and scope of the appended claims. Accordingly, the present invention should not be limited to the embodiments as described above, but should further include all modifications and equivalents thereof within the spirit and scope of the description provided herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'état du système immunitaire d'un sujet après administration d'un stimulant ou d'un inhibiteur de l'immunité d'intérêt est évalué au moyen d'un agent de modulation de l'immunité (IMA) (par exemple un stimulant ou un inhibiteur de l'immunité d'intérêt), par exemple un vaccin contre le cancer, dans le cadre d'une analyse, en vue du traitement d'une maladie ou d'une affection, ou pour déterminer si le sujet est un bon candidat à un tel traitement. Les produits, et de préférence, les profils des produits, générés par les cellules immunitaires du sujet devant recevoir ou ayant reçu un stimulant ou un inhibiteur de l'immunité sont détectés in vitro en exposant un échantillon biologique prélevé chez le sujet au même stimulant ou inhibiteur de l'immunité ou à l'un ou plusieurs de ses composants, puis en dosant (mesurant) au moins un produit associé à au moins une réponse immunologique. Les modifications affectant les profils d'expression caractéristiques dudit IMA sont utilisées pour évaluer le succès ou l'échec du traitement.
PCT/US2013/060606 2012-09-20 2013-09-19 Procédé de détermination de la réponse immunitaire cellulaire aux vaccins thérapeutiques WO2014047278A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261703481P 2012-09-20 2012-09-20
US61/703,481 2012-09-20

Publications (1)

Publication Number Publication Date
WO2014047278A1 true WO2014047278A1 (fr) 2014-03-27

Family

ID=50341931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/060606 WO2014047278A1 (fr) 2012-09-20 2013-09-19 Procédé de détermination de la réponse immunitaire cellulaire aux vaccins thérapeutiques

Country Status (1)

Country Link
WO (1) WO2014047278A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105445469A (zh) * 2014-08-29 2016-03-30 北京九强生物技术股份有限公司 一种缺血修饰白蛋白的检测试剂盒

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
US6143883A (en) * 1998-12-31 2000-11-07 Marlyn Nutraceuticals, Inc. Water-soluble low molecular weight beta-glucans for modulating immunological responses in mammalian system
WO2005037293A1 (fr) * 2003-10-16 2005-04-28 Univ Monash Compositions immunomodulatrices et utilisations de celles-ci
WO2009146750A1 (fr) * 2008-06-05 2009-12-10 Montco Cancer Research B.V. Agent modulant l'immunité anticancéreuse
WO2012047317A2 (fr) * 2010-10-08 2012-04-12 The University Of North Carolina At Charlotte Anticorps spécifiques à une tumeur et utilisations de ceux-ci

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
US6143883A (en) * 1998-12-31 2000-11-07 Marlyn Nutraceuticals, Inc. Water-soluble low molecular weight beta-glucans for modulating immunological responses in mammalian system
WO2005037293A1 (fr) * 2003-10-16 2005-04-28 Univ Monash Compositions immunomodulatrices et utilisations de celles-ci
WO2009146750A1 (fr) * 2008-06-05 2009-12-10 Montco Cancer Research B.V. Agent modulant l'immunité anticancéreuse
WO2012047317A2 (fr) * 2010-10-08 2012-04-12 The University Of North Carolina At Charlotte Anticorps spécifiques à une tumeur et utilisations de ceux-ci

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105445469A (zh) * 2014-08-29 2016-03-30 北京九强生物技术股份有限公司 一种缺血修饰白蛋白的检测试剂盒
CN105445469B (zh) * 2014-08-29 2018-05-01 北京九强生物技术股份有限公司 一种缺血修饰白蛋白的检测试剂盒

Similar Documents

Publication Publication Date Title
Paul et al. Biomarkers in multiple sclerosis
US11300574B2 (en) Methods for treating breast cancer and for identifying breast cancer antigens
US20110262468A1 (en) Method for Monitoring Vaccine Response Using Single Cell Network Profiling
CN111440884A (zh) 源于肠道的诊断肌少症的菌群及其用途
CN110621790A (zh) 用于检测、预测和监测癌症的循环rna
JP5706817B2 (ja) ループスのためのバイオマーカー
US11971418B2 (en) Glomerulonephritis biomarkers
US20220319638A1 (en) Predicting response to treatments in patients with clear cell renal cell carcinoma
Schmidt et al. 88MO T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo) adjuvant patients with triple negative breast cancer
CN111344568A (zh) 预测对免疫疗法的反应
KR102415457B1 (ko) 폐암 진단용 다중 바이오마커 및 이의 용도
CN109991417B (zh) 一种结核病的免疫标志物及应用
TW201918560A (zh) 一種用於檢測、預測和監測癌症的循環rna
US20200378966A1 (en) Multiplexed assay kits for evaluation of systemic lupus erythematosus
WO2014047278A1 (fr) Procédé de détermination de la réponse immunitaire cellulaire aux vaccins thérapeutiques
CN105442053A (zh) 一种检测诊断离子通道病致病基因的dna文库及其应用
Jiang et al. Molecular analysis of inflammatory bowel disease: clinically useful tools for diagnosis, response prediction, and monitoring of targeted therapy
US20190369096A1 (en) Validation of neoepitope-based treatment
CN114746551A (zh) 大肠癌诊断用标志物、辅助大肠癌的诊断的方法、收集数据以用于大肠癌诊断的方法、大肠癌的诊断试剂盒、大肠癌治疗药物、大肠癌的治疗方法、大肠癌的诊断方法
Banerji et al. A circulating biomarker of facioscapulohumeral muscular dystrophy clinical severity, valid in skeletal muscle and blood
Goertsches et al. Multiple sclerosis therapy monitoring based on gene expression
CN112608995B (zh) 一种肺结核病特异性标志物及应用和试剂盒
CN110527721A (zh) 一种陈旧性结核病标志物及其应用
EP3964835A1 (fr) Marqueur pour diagnostiquer un cancer colorectal et procédé pour fournir des informations requises pour le diagnostic du cancer colorectal
WO2008030278A2 (fr) Dosages pour une exposition aux rayonnements

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13839976

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13839976

Country of ref document: EP

Kind code of ref document: A1